Hepatocellular Carcinoma Induced by Viruses: Epidemiological, Clinical and Therapeutic Aspects In Pointe Noire (Congo Brazzaville)

Fs, Ngatali Christian; Alm, Boumba; Ebatetou, A; D, Moukassa; Jb, Nkoua Mbon; Ibara,

doi:10.33425/2639-8478.1040

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…139 A study of 1552 patients with HCC from even countries in Africa reported a median age of HCC onset of 45 years. 146 Individuals born in West Africa had the earliest age of HCC onset (>40 years). 147 Greater than 60% of HCC cases in China, Europe, North America and Korea, are diagnosed at intermediate or advanced stages, resulting in poor outcomes.…”

Section: Geographical and Ethnic Disparity In Hccmentioning

confidence: 99%

“…In contrast, in North America, Japan, USA European nations, the median age at onset is >60 years 139 . A study of 1552 patients with HCC from even countries in Africa reported a median age of HCC onset of 45 years 146 . Individuals born in West Africa had the earliest age of HCC onset (>40 years) 147 .…”

Section: Geographical and Ethnic Disparity In Hccmentioning

confidence: 99%

“… 166 The combination of miRNAs and DNA methylation inactivate various tumor suppressor genes. 166 A recent study by Varghese et al 146 reported ethnic disparities in the miRNA sequences and DNA methylation patterns of in liver tissue samples from individuals with HCC. The expression of miRNAs, such as miR‐150, miR‐155 and miR‐146a, were upregulated in HCV‐infected African–American patients, compared to European Americans.…”

Section: Geographical and Ethnic Disparity In Hccmentioning

confidence: 99%

See 2 more Smart Citations

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

et al. 2023

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. The incidence of HCC is affected by genetic and non‐genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT‐rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6‐phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E‐cadherin, have been shown to contribute to the occurrence of HCC. Non‐genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non‐alcoholic fatty liver disease (NAFLD), increase the risk of HCC.Recent FindingsThe severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non‐minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non‐Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC.ConclusionAssessment and treatment of HCC must be consistent using evidence‐based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.

show abstract

Section: Geographical and Ethnic Disparity In Hccmentioning

confidence: 99%